Regulatory Clearances of IND Applications for CR-001 & CR-003 for the Treatment of Solid Tumors Announced January 11, 2026
FDA Clears IND for A2B543 for Mesothelin-expressing Solid Tumors lacking HLA-A*02 Expression January 11, 2026
Insilico Medicine Announces US$888M Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology January 4, 2026
Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Gen Radionuclide Drug Conjugates January 4, 2026
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly January 4, 2026
Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Gen Radionuclide Drug Conjugates December 30, 2025
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly December 30, 2025
Oncodesign Precision Medicine and Navigo Proteins announce the end of their collaboration in the development of radiotheranostics December 30, 2025
GMP Manufacturing of AKTX-101 ADC Program Initiated to Support Ph 1 First-in-Human Clinical Trial December 30, 2025
Pidnarulex (CX-5461) – Enhertu combo to be evaluated in Ph 1b trial in HER2-positive and HER2-low solid tumors and breast cancer patients December 30, 2025
Caris Life Sciences Announces Collaboration with Genentech to Discover Novel Therapeutic Targets in Cancers with High Unmet Clinical Need December 22, 2025
Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with BMS to Discover and Develop Next-Gen Multi-Specific Antibodies December 22, 2025
Orum Therapeutics Secures ~US$100M to Accelerate Development of Leading Degrader ADC Programs to Treat Serious Diseases December 22, 2025
University of Chicago Extends Collaboration with AbbVie to Advance Clinical Research and Patient Outcomes in Oncology December 22, 2025
CTA submitted in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101) for Solid Tumors December 22, 2025
IND Application to Initiate a Ph 1 Trial of ABP-102/CT-P72 for HER2-positive Cancers submitted to the US FDA December 22, 2025
FDA approves IND to start a Ph 1/2 trial for PM54 + immunotherapy combo in advanced solid tumors December 22, 2025
Oxford BioTherapeutics Enters into a Strategic Collaboration with GSK to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer December 15, 2025
